We herewith submit Audited Financial Results for the Quarter and year ended on March 31, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Link Pharma Chem Ltd reported a continued loss for FY25, though narrower than the previous year. Revenue from operations fell to Rs 2,543.34 lakhs from Rs 2,989.77 lakhs in FY24, a drop of about 15%. The company posted a net loss of Rs 102.73 lakhs in FY25 versus a loss of Rs 136.29 lakhs in FY24, with EPS of Rs (2.31) vs Rs (3.07). Q4 FY25 revenue dropped to Rs 644.66 lakhs from Rs 803.24 lakhs in Q4 FY24, swinging from a small profit to a loss of Rs 35.02 lakhs. The balance sheet shrank modestly, but total borrowings declined sharply from Rs 922 lakhs to Rs 578 lakhs, and operating cash flow turned positive at Rs 268.59 lakhs vs a near-zero figure last year. Auditor CNK & Associates issued an unmodified opinion.
Continued top-line decline and losses are negative for shareholders, but the narrower loss, debt reduction, and positive operating cash flow suggest some operational improvement. The stock may remain under pressure given the persistent unprofitability.